Skip to main content
. 2012 Sep;56(9):4630–4639. doi: 10.1128/AAC.00477-12

Table 4.

Activity (MIC50) of BZT compounds against azole-resistant strains of C. albicansa

Strain Mechanism of resistanceb MIC50 of BZT compounds MIC50 of fluconazole Source or referencec
CAF2/SC5314 Sensitive 1.6 0.2 This paper
95-68 CDR overexpression 1.6–3.2 >64 35, 59
FH5 CDR overexpression 1.6 64 35, 59
96-25 MDR + ERG11 overexpression 1.6 32 35, 59
C17 (12–99) CDR + MDR + ERG11 overexpression 1.6–3.2 >64 35, 59
DSY1764 Erg11/erg11erg3/erg3 1.6–3.2 >128 16, 17
DSY296 TAC1-5/TAC1-5 ERG11-5/ERG11-5 1.6–3.2 >64 16, 17
B4 Mrr1p mutation (G878E/G878E) 1.6–3.2 12.5 39
CAAL-61 AA G307S, Y447H 1.6–3.2 >64 38
CAAL-74 AA Y132F, G448V 1.6–3.2 >64 38
CAAL-75 AA Y132H, K143R 1.6–3.2 >64 38
a

Strain numbers, mechanisms of resistance, and MIC50 values are shown. The MIC50 values reflect the range of concentrations for all BZT compounds against all strains.

b

AA, amino acid point mutants of erg11.

c

References describe the source and/or resistance mechanisms.